103 related articles for article (PubMed ID: 17100982)
1. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis.
Montalto M; Curigliano V; Santoro L; Armuzzi A; Cammarota G; Covino M; Mentella MC; Ancarani F; Manna R; Gasbarrini A; Gasbarrini G
Am J Gastroenterol; 2007 Jan; 102(1):132-6. PubMed ID: 17100982
[TBL] [Abstract][Full Text] [Related]
2. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome.
Langhorst J; Junge A; Rueffer A; Wehkamp J; Foell D; Michalsen A; Musial F; Dobos GJ
Am J Gastroenterol; 2009 Feb; 104(2):404-10. PubMed ID: 19174795
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin concentrations in untreated coeliac patients.
Montalto M; Santoro L; Curigliano V; D'Onofrio F; Cammarota G; Panunzi S; Ricci R; Gallo A; Grieco A; Gasbarrini A; Gasbarrini G
Scand J Gastroenterol; 2007 Aug; 42(8):957-61. PubMed ID: 17613925
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis.
Bergquist A; Montgomery SM; Bahmanyar S; Olsson R; Danielsson A; Lindgren S; Prytz H; Hultcrantz R; Lööf LA; Sandberg-Gertzén H; Almer S; Askling J; Ehlin A; Ekbom A
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):939-43. PubMed ID: 18674735
[TBL] [Abstract][Full Text] [Related]
6. [Significance of fecal lactoferrin in evaluation of disease activity in ulcerative colitis].
Xiang JY; Ouyang Q; Li GD
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2262-4. PubMed ID: 18001547
[TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth.
Montalto M; Santoro L; Dalvai S; Curigliano V; D'Onofrio F; Scarpellini E; Cammarota G; Panunzi S; Gallo A; Gasbarrini A; Gasbarrini G
Dig Dis; 2008; 26(2):183-6. PubMed ID: 18431069
[TBL] [Abstract][Full Text] [Related]
8. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis.
Johnson MW; Maestranzi S; Duffy AM; Dewar DH; Forbes A; Bjarnason I; Sherwood RA; Ciclitira P; Nicholls JR
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):174-9. PubMed ID: 18301296
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and inflammatory faecal markers in collagenous colitis.
Wildt S; Nordgaard-Lassen I; Bendtsen F; Rumessen JJ
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):567-74. PubMed ID: 17556903
[TBL] [Abstract][Full Text] [Related]
10. [Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests].
Malícková K; Janatková I; Bortlík M; Komárek V; Lukás M
Epidemiol Mikrobiol Imunol; 2008 Nov; 57(4):147-53. PubMed ID: 19069028
[TBL] [Abstract][Full Text] [Related]
11. Role of fecal calprotectin in the diagnosis and treatment of segmental colitis associated with diverticulosis.
Tursi A; Elisei W; Giorgetti G; Aiello F; Brandimarte G
Minerva Gastroenterol Dietol; 2011 Sep; 57(3):247-55. PubMed ID: 21769075
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of breast cancer in first-degree relatives of Crohn's disease patients. An IG-IBD study.
Riegler G; Caserta L; Castiglione F; Esposito I; Valpiani D; Annese V; Zoli G; Gionchetti P; Viscido A; Sturniolo GC; Rispo A; De Filippo FR; de Leone A; Carratu R;
Dig Liver Dis; 2006 Jan; 38(1):18-23. PubMed ID: 16169781
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
[TBL] [Abstract][Full Text] [Related]
14. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
Gisbert JP; McNicholl AG
Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis.
Gundling F; Schmidtler F; Hapfelmeier A; Schulte B; Schmidt T; Pehl C; Schepp W; Seidl H
Liver Int; 2011 Oct; 31(9):1406-15. PubMed ID: 22093455
[TBL] [Abstract][Full Text] [Related]
16. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland.
Thjodleifsson B; Geirsson AJ; Björnsson S; Bjarnason I
Arthritis Rheum; 2007 Aug; 56(8):2633-9. PubMed ID: 17665420
[TBL] [Abstract][Full Text] [Related]
17. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
18. [Expression of calprotectin in colon mucosa and fecal of patients with ulcerative colitis].
Liu WB; Lü YM; Jin Z; Yang XL
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 37(2):179-82. PubMed ID: 15841150
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner.
Tedde A; Laura Putignano A; Bagnoli S; Congregati C; Milla M; Sorbi S; Genuardi M; Papi L
Scand J Gastroenterol; 2008; 43(6):712-8. PubMed ID: 18569989
[TBL] [Abstract][Full Text] [Related]
20. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
